Kodiak Sciences (NASDAQ:KOD) Director Buys $8,514,416.32 in Stock

Kodiak Sciences Inc. (NASDAQ:KOD) Director Bros. Advisors Lp Baker bought 86,432 shares of the business’s stock in a transaction on Thursday, November 5th. The stock was bought at an average cost of $98.51 per share, with a total value of $8,514,416.32. Following the completion of the purchase, the director directly owned 20,424,859 shares in the company, valued at approximately $2,012,052,860.09. The trade was a 0.42% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Wednesday, November 4th, Bros. Advisors Lp Baker purchased 160,658 shares of Kodiak Sciences stock. The shares were purchased at an average cost of $98.51 per share, for a total transaction of $15,826,419.58.
• On Monday, September 28th, Bros. Advisors Lp Baker purchased 807,840 shares of Kodiak Sciences stock. The shares were purchased at an average cost of $72.57 per share, for a total transaction of $58,624,948.80.
• On Monday, September 28th, Bros. Advisors Lp Baker acquired 418,323 shares of Kodiak Sciences stock. The stock was purchased at an average cost of $83.58 per share, with a total value of $34,963,436.34.
• On Tuesday, September 29th, Bros. Advisors Lp Baker acquired 33,726 shares of Kodiak Sciences stock. The stock was purchased at an average cost of $85.05 per share, with a total value of $2,868,396.30.
• On Monday, September 28th, Bros. Advisors Lp Baker acquired 681,866 shares of Kodiak Sciences stock. The shares were purchased at an average price of $88.77 per share, with a total value of $60,529,244.82.

Kodiak Sciences Stock Performance

Kodiak Sciences stock opened at $99.30 on Monday. Kodiak Sciences Inc. has a 12-month low of $15.83 and a 12-month high of $104.00. The stock has a market cap of $6.24 billion, a P/E ratio of -23.70 and a beta of 2.02. The company has a 50-day moving average price of $69.56 and a 200 day moving average price of $43.69.

Kodiak Sciences (NASDAQ:KOD) last posted its earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.09). As a group, analysts forecast that Kodiak Sciences Inc. will post -3.97 EPS for the current year.

Institutional Trading of Kodiak Sciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Kodiak Sciences in the second quarter valued at about $161,113,000. Jupiter Topco LLC purchased a new position in Kodiak Sciences during the second quarter worth about $59,507,000. ICONIQ Capital LLC purchased a new position in Kodiak Sciences during the second quarter worth about $49,345,000. Bank of America Corp DE acquired a new stake in shares of Kodiak Sciences during the second quarter valued at about $14,949,000. Finally, Boone Capital Management LLC acquired a new stake in shares of Kodiak Sciences during the second quarter valued at about $14,727,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on KOD shares. The Goldman Sachs Group initiated coverage on shares of Kodiak Sciences in a research report on Wednesday, September 30th. They set a “neutral” rating and a $103.00 price target on the stock. Lifesci Capital upped their price objective on Kodiak Sciences from $85.00 to $145.00 and gave the company an “outperform” rating in a report on Monday, September 28th. Wall Street Zen upgraded Kodiak Sciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, October 4th. Jefferies Financial Group reiterated a “buy” rating and issued a $112.00 price objective on shares of Kodiak Sciences in a research report on Monday, September 28th. Finally, UBS Group raised their target price on Kodiak Sciences from $80.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, September 28th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.71.

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company’s research centers on therapies designed to address conditions that can cause vision loss, including diabetic macular edema, neovascular age-related macular degeneration and retinal vein occlusion.

Kodiak’s proprietary Antibody Biopolymer Conjugate platform is designed to combine the targeting capabilities of antibody-based medicines with a biodegradable polymer intended to extend the duration of treatment in the eye.